What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His main research concerns Melanoma, Internal medicine, Oncology, Surgery and Cancer research.
Dirk Schadendorf studies Vemurafenib which is a part of Melanoma.
In his research on the topic of Internal medicine, Survival rate and Intention-to-treat analysis is strongly related with Gastroenterology.
Dirk Schadendorf interconnects Meta-analysis and MEK inhibitor in the investigation of issues within Oncology.
While the research belongs to areas of Cancer research, Dirk Schadendorf spends his time largely on the problem of Gene, intersecting his research to questions surrounding Molecular biology and PTEN.
His Ipilimumab study combines topics in areas such as Pembrolizumab, Nivolumab, Adverse effect and Skin cancer.
His most cited work include:
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. (10003 citations)
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
What are the main themes of his work throughout his whole career to date?
Dirk Schadendorf mainly focuses on Melanoma, Internal medicine, Oncology, Cancer research and Immunology.
He works on Melanoma which deals in particular with Vemurafenib.
His research on Internal medicine frequently links to adjacent areas such as Surgery.
His Surgery study integrates concerns from other disciplines, such as Gastroenterology and Adverse effect.
His study in Oncology is interdisciplinary in nature, drawing from both Metastatic melanoma, Chemotherapy, Phases of clinical research and Hazard ratio.
His Cancer research research focuses on subjects like Gene, which are linked to Molecular biology.
He most often published in these fields:
- Melanoma (53.82%)
- Internal medicine (38.74%)
- Oncology (29.22%)
What were the highlights of his more recent work (between 2017-2021)?
- Melanoma (53.82%)
- Internal medicine (38.74%)
- Oncology (29.22%)
In recent papers he was focusing on the following fields of study:
Dirk Schadendorf spends much of his time researching Melanoma, Internal medicine, Oncology, Cancer research and Immunotherapy.
His studies in Melanoma integrate themes in fields like Immune checkpoint, Blockade, MEK inhibitor, Immune system and Targeted therapy.
His study in the field of Clinical trial, Ipilimumab and Dabrafenib also crosses realms of In patient.
Dirk Schadendorf usually deals with Ipilimumab and limits it to topics linked to Nivolumab and Progression-free survival.
His Oncology study also includes
- Phases of clinical research which intersects with area such as Adverse effect,
- Pembrolizumab, which have a strong connection to Hazard ratio.
In Cancer research, Dirk Schadendorf works on issues like T cell, which are connected to Cytotoxic T cell.
Between 2017 and 2021, his most popular works were:
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (659 citations)
- Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine (594 citations)
- Pan-cancer analysis of whole genomes (538 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Melanoma, Oncology, Cancer research and Clinical trial.
In his study, Clinical endpoint is inextricably linked to Placebo, which falls within the broad field of Internal medicine.
Specifically, his work in Melanoma is concerned with the study of Cutaneous melanoma.
His Oncology research is multidisciplinary, relying on both Pembrolizumab, Cancer and Binimetinib, MEK inhibitor, Vemurafenib.
His Clinical trial research includes elements of Randomized controlled trial and Survival analysis.
His work deals with themes such as Gastroenterology and Nivolumab, which intersect with Ipilimumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
